Bel Fuse (BELFA) Reports Q1 EPS of $0.07
Get Alerts BELFA Hot Sheet
Price: $237.51 --0%
Financial Fact:
Income from operations: 9.31M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Financial Fact:
Income from operations: 9.31M
Today's EPS Names:
VAXX, NMRD, EGRX, More
Join SI Premium – FREE
Bel Fuse (NASDAQ: BELFA) reported Q1 EPS of $0.07. Revenue for the quarter came in at $113.7 million, versus $0 reported last year.
First Quarter 2017 Highlights
- Net sales were $113.7 million for the first quarter of 2017, representing a 6.2% decline from $121.2 million in the first quarter of 2016.
- Gross profit margin improved to 20.5% in the first quarter of 2017, up from 19.0% in the first quarter of 2016 due to cost savings realized on prior year restructuring efforts and a more favorable product mix in the first quarter of 2017.
- Net earnings increased to $0.7 million in the first quarter of 2017. This compares to a net loss of $100.7 million in the same period of 2016, which resulted primarily from a $108.6 million impairment charge on goodwill and other intangible assets as further described below.
- Class A earnings per share was $0.05 on a GAAP basis (compared to a net loss per share of $8.15 in the first quarter of 2016) and earnings of $0.07 per share on a Non-GAAP basis (compared to $0.04 in the first quarter of 2016).
- Class B earnings per share was $0.06 on a GAAP basis (compared to a net loss per share of $8.55 in the first quarter of 2016) and earnings of $0.09 per share on a Non-GAAP basis (compared to $0.05 in the first quarter of 2016).
For earnings history and earnings-related data on Bel Fuse (BELFA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
- Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
- Zenas BioPharma, Inc. (ZBIO) Reports Q2 Loss of $1.77
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share